Dergiler / Eurasian Journal of Medicine / 2022 / Cilt: 54 - Sayı: 1

Everolimus and/or Nivolumab-Associated Cytomegalovirus Colitis in a Patient with Metastatic Renal Cell Carcinoma

Sayfa
77–79
Yayın Tarihi
2022-10-18
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Further studies are needed to elucidate the relationship between immune checkpoint inhibitors and cytomegalovirus reactivation, and these will also be a guide to prevent other possible viral infections.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Everolimus-associated cytomegalovirus colitis is very rare in cancer patients.
📊
Temel Bulgular & Veri:We present a case of cytomegalovirus colitis that occurred on using everolimus in a 64-year-old male with metastatic renal cell carcinoma who received pazopanib, nivolumab, and everolimus treatments, respectively.
💡
Sonuç & Katkı:Further studies are needed to elucidate the relationship between immune checkpoint inhibitors and cytomegalovirus reactivation, and these will also be a guide to prevent other possible viral infections.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Everolimus-associated cytomegalovirus colitis is very rare in cancer patients. We present a case of cytomegalovirus colitis that occurred on using everolimus in a 64-year-old male with metastatic renal cell carcinoma who received pazopanib, nivolumab, and everolimus treatments, respectively. Although an increasing number of nivolumab-related cytomegalovirus colitis cases are reported recently, its mechanism of development is still unknown. Our study highlights that clinicians should remember cytomegalovirus reactivation in the presence of diarrhea or colitis in patients receiving everolimus and/or nivolumab. Further studies are needed to elucidate the relationship between immune checkpoint inhibitors and cytomegalovirus reactivation, and these will also be a guide to prevent other possible viral infections.

🔖

Bu Makaleye Atıf Yap

ISMAYILOV, R., AKTEPE, O. H., LEBLEBİCİ, C. B., ERMAN, M., SARDAROVA, K. (2022). Everolimus and/or Nivolumab-Associated Cytomegalovirus Colitis in a Patient with Metastatic Renal Cell Carcinoma. Eurasian Journal of Medicine, Cilt: 54 - Sayı: 1, 77–79. https://ajindex.com/articles/508779

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008
  2. 372(9637):449-456. [CrossRef] 2. Tan L, Sato N, Shiraki A, et al. Everolimus delayed and suppressed cytomegalovirus DNA synthesis, spread of the infection, and alleviated cytomegalovirus infection. Antiviral Res. 2019
  3. [CrossRef] 3. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019
  4. 30(5):706-720. [CrossRef] 4. Havenith SHC, Yong SL, Van Donselaar-Van Der Pant KAMI, van Lier RA, ten Berge IJ, Bemelman FJ. Everolimus-treated renal transplant recipients have a more robust CMV-specific CD8+ T-cell response compared with cyclosporine-or mycophenolate-treated patients. Transplantation. 2013
  5. 95(1):184-191. [CrossRef] 5. Yang JR, Shao YC. Everolimus-associated cytomegalovirus colitis in a patient with metastasized breast cancer: a case report. Breast Cancer. 2020
  6. 27(4):776-779. [CrossRef] 6. Prieux-Klotz C, Dior M, Damotte D, et al. Immune checkpoint inhibitor-induced colitis: diagnosis and management. Target Oncol. 2017
  7. 12(3):301-308. [CrossRef] 7. Weber JS, D’Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015
  8. 16(4):375-384. [CrossRef] 8. Assarzadegan N, Montgomery E, Anders RA. Immune checkpoint inhibitor colitis: the flip side of the wonder drugs. Virchows Arch. 2018
  9. 472(1):125-133. [CrossRef] 9. Lankes K, Hundorfean G, Harrer T, et al. AntiTNF-refractory colitis after checkpoint inhibitor therapy: possible role of CMV-mediated immunopathogenesis. Oncoimmunology. 2016
  10. 5(6):e1128611. [CrossRef] 10. Franklin C, Rooms I, Fiedler M, et al. Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis. Eur J Cancer. 2017
  11. [CrossRef] 11. Cañete F, Mañosa M, Lobatón T, et al. Nivolumabinduced immune-mediated colitis: an ulcerative colitis look-alike—report of new cases and review of the literature. Int J Colorectal Dis. 2019
  12. 34(5):861-865. [CrossRef] 12. Van Turenhout ST, Berghuis M, Snaebjornsson P, et al. Cytomegalovirus in steroid-refractory immune checkpoint inhibition–related colitis. J Thorac Oncol. 2020
  13. 15(1):e15-e20. [CrossRef] 13. Medicines and Healthc